Whitepaper: Profiling oncology candidates
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
In this whitepaper, we describe a profiling strategy that includes both in vitro and in vivo approaches to characterise sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types. Data for vemurafenib, an anti-neoplastic B-Raf kinase inhibitor, is also included to highlight how profiling compounds can shed light onto potentially different applications in the clinic.
Related content from this organisation
- Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
- SH2 domains as a target class in cancer and inflammation
- Cardiac and vascular safety liabilities using totality of evidence approach
- Decoding cancer and inflammation: identifying selective inhibitors of SH2 domains
- Comprehensive in vitro approach to evaluate transporter-mediated drug interactions in drug discovery